Table 3.

Progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), NSE adjusted, chromogranin A (CgA), and squamous cell carcinoma antigen 1 (SCCA1) values in the pulmonary neuroendocrine tumors (PNET), non-small-cell lung carcinoma (NSCLC), benign, and healthy groups.

	n (%)
PNET (n = 23)Carcinoid tumors (n = 9) 1a2 1a3 1b 2a 2b 4a Small cell lung cancer (n = 14)Limited stage diseaseExtensive stage disease	1 (11.1)3 (33.3)1 (11.1)1 (11.1)2 (22.2)1 (11.1)1 (7.1)13 (92.9)
NSCLC (n = 28) 1a2 1a3 1b 2b 3a 3b 3c 4a 4b	1 (3.6)1 (3.6)1 (3.6)1 (3.6)2 (7.1)5 (17.9)2 (7.1)8 (28.6)7 (25)

Values are given as median (25%–75%). *: The difference was due to the high ProGRP levels in patients with PNET. #: The difference was due to the high NSE levels in patients with PNET. &: The difference was due to the high NSE adjusted levels in patients with PNET.